In Vitro Activity of a Novel Antifungal Compound, MYC-053, against Clinically Significant Antifungal-Resistant Strains of Candida glabrata, Candida auris, Cryptococcus neoformans, and Pneumocystis spp.

An urgent need exists for new antifungal compounds to treat fungal infections in immunocompromised patients. The aim of the current study was to investigate the potency of a novel antifungal compound, MYC-053, against the emerging yeast and yeast-like pathogens Candida glabrata, Candida auris, Crypt...

Descripción completa

Detalles Bibliográficos
Autores principales: Tetz, G., Collins, M., Vikina, D., Tetz, V.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Microbiology 2019
Materias:
Experimental Therapeutics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6437499/
https://www.ncbi.nlm.nih.gov/pubmed/30917977
http://dx.doi.org/10.1128/AAC.01975-18

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6437499/
https://www.ncbi.nlm.nih.gov/pubmed/30917977
http://dx.doi.org/10.1128/AAC.01975-18

Ejemplares similares